Zhanzhan Feng

505 total citations
19 papers, 395 citations indexed

About

Zhanzhan Feng is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Zhanzhan Feng has authored 19 papers receiving a total of 395 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Hematology. Recurrent topics in Zhanzhan Feng's work include Protein Degradation and Inhibitors (6 papers), Ubiquitin and proteasome pathways (6 papers) and Histone Deacetylase Inhibitors Research (4 papers). Zhanzhan Feng is often cited by papers focused on Protein Degradation and Inhibitors (6 papers), Ubiquitin and proteasome pathways (6 papers) and Histone Deacetylase Inhibitors Research (4 papers). Zhanzhan Feng collaborates with scholars based in China, Netherlands and United States. Zhanzhan Feng's co-authors include Luoting Yu, Zhihao Liu, Cuiting Peng, Xi Hu, Yong Xia, Tiantao Gao, Jun Zeng, Ningyu Wang, Qian Lei and Wei Wei and has published in prestigious journals such as Journal of Medicinal Chemistry, Biochemical Pharmacology and Cancer Letters.

In The Last Decade

Zhanzhan Feng

19 papers receiving 390 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhanzhan Feng China 14 273 102 61 50 38 19 395
C-T Yeh Taiwan 7 277 1.0× 75 0.7× 26 0.4× 77 1.5× 32 0.8× 7 389
Jacqueline Sayyah United States 9 368 1.3× 178 1.7× 29 0.5× 21 0.4× 47 1.2× 11 534
Deborah Moshinsky United States 11 270 1.0× 166 1.6× 31 0.5× 31 0.6× 21 0.6× 14 431
Sathyen A. Prabhu United States 9 321 1.2× 94 0.9× 27 0.4× 61 1.2× 31 0.8× 12 454
Min Soo Kim South Korea 10 254 0.9× 156 1.5× 24 0.4× 22 0.4× 52 1.4× 20 434
Amriti R. Lulla United States 11 277 1.0× 135 1.3× 12 0.2× 60 1.2× 42 1.1× 24 434
Alain Laroze France 7 234 0.9× 79 0.8× 55 0.9× 20 0.4× 25 0.7× 11 400
Jung Yoo South Korea 14 400 1.5× 122 1.2× 28 0.5× 51 1.0× 38 1.0× 19 529
Nicolas Warin United Kingdom 4 222 0.8× 115 1.1× 111 1.8× 18 0.4× 50 1.3× 7 394
Takahiro Domoto Japan 11 334 1.2× 157 1.5× 18 0.3× 43 0.9× 39 1.0× 20 503

Countries citing papers authored by Zhanzhan Feng

Since Specialization
Citations

This map shows the geographic impact of Zhanzhan Feng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhanzhan Feng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhanzhan Feng more than expected).

Fields of papers citing papers by Zhanzhan Feng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhanzhan Feng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhanzhan Feng. The network helps show where Zhanzhan Feng may publish in the future.

Co-authorship network of co-authors of Zhanzhan Feng

This figure shows the co-authorship network connecting the top 25 collaborators of Zhanzhan Feng. A scholar is included among the top collaborators of Zhanzhan Feng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhanzhan Feng. Zhanzhan Feng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Feng, Zhanzhan, et al.. (2024). A novel selective FAK inhibitor E2 inhibits ovarian cancer metastasis and growth by inducing cytotoxic autophagy. Biochemical Pharmacology. 229. 116461–116461. 2 indexed citations
2.
Feng, Zhanzhan, Shirui Wang, Su Jong Yu, et al.. (2024). Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer. European Journal of Medicinal Chemistry. 277. 116780–116780. 2 indexed citations
3.
Wang, Shirui, Zhanzhan Feng, Can Qu, et al.. (2024). Novel Amphiphilic PROTAC with Enhanced Pharmacokinetic Properties for ALK Protein Degradation. Journal of Medicinal Chemistry. 67(12). 9842–9856. 19 indexed citations
4.
Zhang, Yan, Zhanzhan Feng, Shuai Ming, et al.. (2024). Discovery of Novel Proteolysis-Targeting Chimera Molecules as Degraders of Programmed Cell Death-Ligand 1 for Breast Cancer Therapy. Journal of Medicinal Chemistry. 67(13). 10589–10600. 4 indexed citations
5.
Wang, Shirui, Dan Luo, Chunlan Pu, et al.. (2023). Discovery of the GSH responsive “Y-PROTACs” targeting ALK and CDK4/6 as a potential treatment for cancer. European Journal of Medicinal Chemistry. 248. 115082–115082. 20 indexed citations
6.
Li, Xiao, Qianqian Wang, Xuejiao Song, et al.. (2023). A novel VEGFR inhibitor ZLF-095 with potent antitumor activity and low toxicity. Heliyon. 9(5). e15152–e15152. 4 indexed citations
7.
Feng, Zhanzhan, Qiangsheng Zhang, Xiao Li, et al.. (2022). Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer. Journal of Medicinal Chemistry. 65(24). 16541–16569. 18 indexed citations
8.
Wei, Wei, Zhanzhan Feng, Zhihao Liu, et al.. (2021). Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer. European Journal of Medicinal Chemistry. 228. 113978–113978. 18 indexed citations
9.
Zeng, Jun, Zhanzhan Feng, Xiang Wang, et al.. (2021). Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors. European Journal of Medicinal Chemistry. 220. 113499–113499. 21 indexed citations
10.
Hu, Xi, Lu Li, Qiangsheng Zhang, et al.. (2020). Design, synthesis and biological evaluation of a novel tubulin inhibitor SKLB0565 targeting the colchicine binding site. Bioorganic Chemistry. 97. 103695–103695. 13 indexed citations
11.
Hu, Xi, Fei Teng, Zhihao Liu, et al.. (2020). Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 30(5). 126957–126957. 14 indexed citations
12.
Xu, Ying, Zhihao Liu, Lifeng Zhao, et al.. (2020). Novel Dual BET and PLK1 Inhibitor WNY0824 Exerts Potent Antitumor Effects in CRPC by Inhibiting Transcription Factor Function and Inducing Mitotic Abnormality. Molecular Cancer Therapeutics. 19(6). 1221–1231. 16 indexed citations
13.
Xue, Qiang, Zhihao Liu, Zhanzhan Feng, et al.. (2019). Penfluridol: An antipsychotic agent suppresses lung cancer cell growth and metastasis by inducing G0/G1 arrest and apoptosis. Biomedicine & Pharmacotherapy. 121. 109598–109598. 23 indexed citations
14.
Xu, Fuyan, Yong Xia, Zhanzhan Feng, et al.. (2019). Repositioning antipsychotic fluphenazine hydrochloride for treating triple negative breast cancer with brain metastases and lung metastases.. PubMed. 9(3). 459–478. 41 indexed citations
15.
Wu, Yuangang, Mingyang Li, Jun Zeng, et al.. (2019). Differential Expression of Renin-Angiotensin System-related Components in Patients with Rheumatoid Arthritis and Osteoarthritis. The American Journal of the Medical Sciences. 359(1). 17–26. 27 indexed citations
16.
Feng, Zhanzhan, Yao Shi, Jing Ren, et al.. (2019). Design, synthesis and biological evaluation of 3,5-dimethylisoxazole and pyridone derivatives as BRD4 inhibitors. Bioorganic & Medicinal Chemistry Letters. 29(19). 126577–126577. 5 indexed citations
17.
Gao, Tiantao, Xi Hu, Qian Lei, et al.. (2018). Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis. Cancer Letters. 445. 11–23. 32 indexed citations
18.
Lei, Qian, Lu Xiong, Yong Xia, et al.. (2018). YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect. Cell Death and Disease. 9(11). 1066–1066. 48 indexed citations
19.
Feng, Zhanzhan, Yong Xia, Tiantao Gao, et al.. (2018). The antipsychotic agent trifluoperazine hydrochloride suppresses triple-negative breast cancer tumor growth and brain metastasis by inducing G0/G1 arrest and apoptosis. Cell Death and Disease. 9(10). 1006–1006. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C-T Yeh Breakdown of academic impact, for papers by Jacqueline Sayyah Breakdown of academic impact, for papers by Deborah Moshinsky Breakdown of academic impact, for papers by Sathyen A. Prabhu Breakdown of academic impact, for papers by Min Soo Kim Breakdown of academic impact, for papers by Amriti R. Lulla Breakdown of academic impact, for papers by Alain Laroze Breakdown of academic impact, for papers by Jung Yoo Breakdown of academic impact, for papers by Nicolas Warin Breakdown of academic impact, for papers by Takahiro Domoto
Rankless by CCL
2026